Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial
de Latour, R. P., Szer, J., Weitz, I. C., Röth, A., Höchsmann, B., Panse, J., Usuki, K., Griffin, M., Kiladjian, J. J., de Castro, C. M., Nishimori, H., Ajayi, T., Al-Adhami, M., Deschatelets, P., Francois, C., Grossi, F., Risitano, A. M., & Hillmen, P. (2022). Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): […]